ArticleBMC medical imaging2026
Contrast-enhanced ultrasound for reclassification of moderate-risk carotid plaques (Plaque-RADS 3).
Article in BMC medical imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundThe Carotid Plaque-RADS system has been proposed to standardize carotid plaque evaluation recently. However, the carotid plaques classified into plaque-RADS 3 share considerable heterogeneity, which poses challenges for clinical management. This research aimed to investigate the supplementary value of contrast-enhanced ultrasound (CEUS) in assessing these moderate-risk carotid plaques designated as plaque-RADS 3.
methodsA retrospective diagnostic analysis was conducted on 194 patients (270 plaques) who underwent carotid plaque CEUS from January 2020 to May 2024. Plaque features and patients' characteristics were retrieved. CEUS videos were independently reviewed by two senior radiologists, and intraplaque neovascularization (IPN) intensity was graded semi-quantitatively using a four point score system (0 = no enhancement; 1 = spotty enhancement; 2 = spotty and 1-2 short linear enhancements; 3 = linear enhancement traversing the plaque). Plaques were subclassified into 3a, 3b, and 3c groups based on the Carotid Plaque-RADS criteria proposed by saba et al. Differences in IPN among subgroups and their association with symptomatic plaques were analyzed using multivariate logistic regression.
resultsAmong 270 plaques, 92 were classified as 3a, 146 as 3b, and 32 as 3c. No significant differences were observed in age, gender, plaque echogenicity, length, thickness, or lumen stenosis severity among groups. Multivariate logistic regression identified luminal stenosis (OR = 2.129, p < 0.001), plaque thickness (OR = 2.429, p < 0.001), length (OR = 1.033, p < 0.001), and IPN (OR = 1.884, p = 0.012) as independent predictors of symptomatic plaques. IPN grading differed significantly across groups (p < 0.001), with 3a plaques showing a higher proportion of low (0-1) IPN scores (40.2% vs. 7.5% in 3b and 6.3% in 3c, p < 0.001). Intra- and inter-observer agreement for IPN grading was good (kappa = 0.762 and 0.704, respectively).
conclusionsApproximately 40.2% of 3a plaques exhibited low IPN score, correlating with possibly reduced symptomatic risk. Despite all Plaque-RADS 3 entities described as stroke-moderate-risk, CEUS-assessed IPN enables further risk stratification-A subset of 3a plaques may warrant reclassification to lower-risk categories. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
42443789What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.